Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pBI-11
- Development stage
- Phase 2
- Lead developer
- PapiVax Biotech
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
pBI-11 is a DNA-based therapeutic vaccine developed for the treatment of human papillomavirus (HPV)-associated diseases. It encodes the E6 and E7 genes of both HPV16 and HPV18 virus types fused to the HSP70 molecular adjuvant. The vaccine is designed to stimulate an immune response against cells expressing these oncogenic viral proteins. In clinical development, it is used as part of a heterologous prime-boost immunization regimen (PVX-7), where pBI-11 DNA vaccine serves as the priming agent followed by a recombinant attenuated vaccinia virus vector (TA-HPV) as booster. The primary indications under investigation include cervical cancer, oropharyngeal cancer, and persistent HPV16/18 infection with low-grade precancerous lesions[1][2].
- Brand names
- PVX-8PVX8PVX 8
- Other names
- pBI11/TAHPV
02
Targets
HPV16 E6 oncoproteinHPV16 E7 (Human papillomavirus 16 E7 protein)HPV18 E7HPV16 E7 TCR (HPV16 E7-specific T-cell receptor)
Beyond the preview
Go deeper on pBI-11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pBI-11.